Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore
December 22 2017 - 4:15PM
Aeterna Zentaris Inc. (the “Company” or “Aeterna Zentaris”)
(NASDAQ:AEZS) (TSX:AEZS), a specialty biopharmaceutical company
engaged in developing and commercializing pharmaceutical therapies,
announced today that it is in receipt of a statement of defence and
counterclaim filed by former officers David Dodd (“Dodd”) and
Philip Theodore (“Theodore”) in Ontario in connection with the
Company’s previously disclosed litigation against Dodd and
Theodore. The counterclaim against the Company and its Chair,
Carolyn Egbert, alleges, among other things, that defamatory
statements in respect of Dodd and Theodore were made in a Company
press release, and claims damages of $6 million.
The Company and its Chair consider the
counterclaim against them to be entirely without merit, and intend
to vigorously defend against the counterclaim.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company focused on developing and commercializing
Macrilen™ (macimorelin), an orally available ghrelin agonist, to be
used in the diagnosis of patients with adult growth hormone
deficiency (AGHD). On December 20, 2017 the Company announced that
the U.S. Food and Drug Administration (FDA) granted marketing
approval for Macrilen™ (macimorelin). On November 27, 2017 Aeterna
Zentaris announced that the Marketing Authorization Application
(MAA) for the use of Macrilen™ (macimorelin) for the evaluation of
AGHD was accepted by the European Medicines Agency (EMA) for
regulatory review. For more information,
visit www.aezsinc.com.
Forward-Looking Statements
This press release contains forward-looking
statements made pursuant to the safe-harbor provisions of the U.S.
Securities Litigation Reform Act of 1995 and applicable Canadian
securities laws, which reflect our current expectations regarding
future events. Forward-looking statements may include, but are not
limited to statements preceded by, followed by, or that include the
words “expects,” “believes,” “intends,” “would,” “could,” “may,”
“anticipates,” and similar terms that relate to future events,
performance, or our results. Forward-looking statements involve
known risks and uncertainties, many of which are discussed under
the caption “Key Information - Risk Factors” in our most recent
Annual Report on Form 20-F filed with the relevant Canadian
securities regulatory authorities in lieu of an annual information
form and with the U.S. Securities and Exchange Commission (“SEC”)
and under the caption “Risk Factors and Uncertainties” in our
management’s discussion and analysis for the third quarter of 2017.
Such statements include, but are not limited to, statements about
the merit or outcome of the litigation involving Dodd and Theodore,
and the Company’s and its Chair’s intention and ability to defend
such legal actions. Known and unknown risks and uncertainties could
cause our actual results to differ materially from those in
forward-looking statements. Such risks and uncertainties include,
effect of the litigation involving Dodd and Theodore and other
litigation, on our cash flow, results of operations and financial
position. Investors should consult the Company’s quarterly and
annual filings with the applicable Canadian securities regulators
and the SEC for additional information on risks and uncertainties.
Given these uncertainties and risk factors, readers are cautioned
not to place undue reliance on these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments,
unless required to do so by a governmental authority or applicable
law.
Contacts:
Aeterna Zentaris Inc.Michael V. WardChief Executive
OfficerIR@aezsinc.com843-900-3201
Reilly ConnectSusan
ReillyPresidentsusan.reilly@reillyconnect.com312-600-6783
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Sep 2023 to Sep 2024